Search

Displaying results 7611 - 7620 of 9709 in total
  1. Drug

    Pidolic acid

    go.drugbank.com/drugs/DB03088
    ApprovedInvestigational

    Pidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics

    Synonyms: 5-L-oxoproline, 5-oxo-L-proline
  2. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary

  3. Drug

    Trifluoroethanol

    go.drugbank.com/drugs/DB03226
    Experimental

    A non-aqueous co-solvent that serves as tool to study protein folding. It is also used in various pharmaceutical, chemical and engineering applications.

  4. Drug

    Glutaral

    go.drugbank.com/drugs/DB03266
    Investigational

    One of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Tetramisole

    go.drugbank.com/drugs/DB16561
    Investigational

    Tetramisole is an anthelmintic agent.

  6. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain. … Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.

  7. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators. … Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.

  8. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor.

  9. Drug

    S-3APG

    go.drugbank.com/drugs/DB17419
    Experimental

    S-3APG (S-3-[3-amino-phthalimido]-glutarimide) is a derivative of thalidomide with dual activity against B-cell neoplasias.[A255168]

  10. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). … Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation.